Indoco Remedies Limited (NSE:INDOCO) reported unaudited standalone financial results for the quarter ended 30 June 2026 on 28 July 2026, showing a net profit of Rs 82.32 crore, compared to a net loss of Rs 28.07 crore in the same quarter of the prior year. The turnaround was primarily driven by an exceptional gain of Rs 97.34 crore recognised from the completed slump sale of the company's Ophthalmic Business Division to Sunways (India) Private Limited. Statutory auditors Gokhale & Sathe issued an unmodified audit opinion on the results.
Key Highlights
- Indoco Remedies reported standalone net profit of Rs 82.32 crore for Q1 FY27, driven by an exceptional gain of Rs 97.34 crore from the sale of its Ophthalmic Business Division to Sunways (India) Private Limited.
- Standalone revenue from operations fell to Rs 408.12 crore in Q1 FY27 from Rs 429.13 crore in Q1 FY26, a year-on-year decline of approximately 4.9 per cent.
- Profit before exceptional items and tax was a loss of Rs 4.12 crore in Q1 FY27, compared to a loss of Rs 28.41 crore in the same quarter last year.
- Consolidated net loss for Q1 FY27 was Rs 19.62 crore before exceptional items, widening from Rs 36.66 crore in Q1 FY26, though consolidated profit before tax including the exceptional gain reached Rs 77.72 crore.
- The statutory auditors highlighted material uncertainty regarding the company's going concern status due to negative net worth of Rs 38.23 crore in the subsidiary FPP Holding LLC, though no impairment provision was recognised following management's assessment.
- Basic and diluted earnings per share for Q1 FY27 were Rs 8.92 per share of face value Rs 2 each, compared to a loss per share of Rs 3.04 in the prior year quarter.
- The Board meeting commenced at 10:45 a.m. and concluded at 11:45 a.m. on 28 July 2026, approving both standalone and consolidated results with limited review reports carrying unmodified audit opinions.
About the Company
Indoco Remedies Limited is a pharmaceutical company incorporated in 1947 and headquartered in Mumbai. The company operates across the Indian and international markets, with revenue generated from both domestic sales (India) and exports (Outside India). In Q1 FY27, domestic sales accounted for Rs 227.75 crore of total revenue from operations of Rs 408.12 crore, with international sales contributing Rs 180.37 crore. The company has a registered office at Indoco House, 166 CST Road, Kalina, Santacruz (East), Mumbai 400 098. Indoco trades on the National Stock Exchange under ticker INDOCO and on the Bombay Stock Exchange under stock code 532612. Its primary reportable business segment is pharmaceuticals. On 28 July 2026, the company completed a strategic divestment by selling its Ophthalmic Business Division to Sunways (India) Private Limited.
Announcement in Detail
Indoco Remedies Limited's Board of Directors, in its meeting held on 28 July 2026, approved the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026 in accordance with Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The approval also included the limited review report issued by statutory auditors M/s. Gokhale & Sathe, Chartered Accountants, which contained an unmodified audit opinion on the unaudited financial results.
On a standalone basis, Indoco reported total income of Rs 413.44 crore in Q1 FY27 against Rs 399.89 crore in Q1 FY26. Revenue from operations, net of other operating income, declined to Rs 408.97 crore from Rs 394.31 crore year-on-year. The company recorded total expenses of Rs 417.56 crore, resulting in a loss before exceptional items and tax of Rs 4.12 crore. However, the company recognised an exceptional gain of Rs 97.34 crore from the completed slump sale of its Ophthalmic Business Division to Sunways (India) Private Limited. This exceptional item elevated profit before tax to Rs 93.22 crore, with tax expenses of Rs 10.90 crore, yielding a net profit of Rs 82.32 crore after accounting for other comprehensive income adjustments of Rs 0.45 crore.
On a consolidated basis, total income reached Rs 469.68 crore compared to Rs 441.30 crore in the prior year quarter. Consolidated revenue from operations rose to Rs 467.50 crore from Rs 439.67 crore year-on-year. However, consolidated total expenses climbed to Rs 489.30 crore, resulting in a loss before exceptional items and tax of Rs 19.62 crore. After inclusion of the same exceptional gain of Rs 97.34 crore and consolidated tax expenses of Rs 15.50 crore (comprising current tax and deferred tax adjustments), consolidated profit before tax reached Rs 77.72 crore. The independent auditors noted in an emphasis of matter that the subsidiary FPP Holding LLC maintained negative net worth of Rs 38.22 crore as at 30 June 2026, creating material uncertainty regarding going concern status, though management's impairment assessment concluded no provision was necessary.
Impact on Investors
Investors will note that Indoco's reported net profit of Rs 82.32 crore in Q1 FY27 is substantially dependent on the Rs 97.34 crore exceptional gain from the ophthalmic business divestment. On an underlying operational basis, the company recorded a loss before exceptional items and tax of Rs 4.12 crore, representing deterioration from the operational loss position. Standalone revenue from operations declined 4.9 per cent year-on-year to Rs 408.12 crore, with domestic sales contributing Rs 227.75 crore and international sales Rs 180.37 crore. The filing shows that core operational profitability remains challenged, with cost of materials consumed, employee benefits, and other expenses combining to exceed operating revenues. This underlying operational weakness should be considered when evaluating the sustainability of reported earnings and the company's cash generation capacity going forward.
The statutory auditors have flagged material uncertainty regarding going concern status due to negative net worth of Rs 38.22 crore in the subsidiary FPP Holding LLC as at 30 June 2026. Although management completed impairment testing and determined no provision was necessary based on review of long-term business plans and cash flow forecasts, investors will observe that this going concern caveat indicates significant financial stress within the consolidated group. The company's ability to service debt and continue operations depends on successful execution of recovery plans in the affected subsidiary. Additionally, the sale of the ophthalmic business division represents a reduction in the company's product portfolio and revenue diversity, which investors should factor into their assessment of medium-term growth prospects and business risk profile. Shareholders should review management's long-term strategic repositioning plans to understand the rationale for divestment and anticipated operational focus going forward.
Sector / Market Context
India's pharmaceutical sector continues to operate within a competitive market characterised by pricing pressures, regulatory compliance requirements, and dual revenue streams from domestic and export markets. Generic drug manufacturers face ongoing cost management challenges as global pricing trends and domestic regulations limit pricing flexibility. The sector comprises companies of varying scale, from multinational players to domestic-focused generics manufacturers. Indoco's reported Q1 FY27 financial performance, with operational losses offset by an exceptional divestment gain, reflects strategic repositioning decisions being taken by mid-tier pharmaceutical companies to optimise asset allocation and focus capital on core therapeutic areas. The company's split between domestic revenue (55.7 per cent of Q1 FY27 operations revenue) and international revenue (44.3 per cent) aligns with the dual-market strategy adopted by many Indian pharmaceutical manufacturers seeking to balance domestic margin pressures with higher-margin export opportunities. The completed sale of the ophthalmic business to Sunways (India) Private Limited signals market consolidation within specialist pharmaceutical segments, with larger or more focused players acquiring niche business units from diversified portfolio holders.